Related Experiment Videos
Adenovirus-mediated interleukin-12 gene therapy for metastatic colon carcinoma
M Caruso1, K Pham-Nguyen, Y L Kwong
1Department of Cell Biology, Baylor College of Medicine, Houston, TX 77030, USA.
Abstract:
Recombinant adenoviral mediated delivery of suicide and cytokine genes has been investigated as a treatment for hepatic metastases of colon carcinoma in mice. Liver tumors were established by intrahepatic implantation of a poorly immunogenic colon carcinoma cell line (MCA-26), which is syngeneic in BALB/c mice. Intratumoral transfer of the herpes simplex virus type 1 thymidine kinase (HSV-tk) and the murine interleukin (mIL)-2 genes resulted in substantial hepatic tumor regression, induced an effective systemic antitumoral immunity in the host and prolonged the median survival time of the treated animals from 22 to 35 days. The antitumoral immunity declined gradually, which led to tumor recurrence over time. A recombinant adenovirus expressing the mIL-12 gene was constructed and tested in the MCA-26 tumor model. Intratumoral administration of this cytokine vector alone increased significantly survival time of the animals with 25% of the treated animals still living over 70 days. These data indicate that local expression of IL-12 may also be an attractive treatment strategy for metastatic colon carcinoma.
Insights
Gene therapy using recombinant adenoviruses showed promise for treating colon cancer liver metastases in mice. Delivery of suicide and cytokine genes led to tumor regression and improved survival, with IL-12 showing particular potential.
Area of Science:
- Oncology
- Gene Therapy
- Immunology
Background:
- Hepatic metastases of colon carcinoma pose a significant clinical challenge.
- Current treatments for liver metastases have limitations.
- Recombinant adenoviral gene delivery offers a potential therapeutic strategy.
Purpose of the Study:
- To investigate the efficacy of recombinant adenoviral gene therapy for hepatic metastases of colon carcinoma in a murine model.
- To evaluate the therapeutic potential of suicide and cytokine genes, specifically herpes simplex virus type 1 thymidine kinase (HSV-tk), murine interleukin-2 (mIL-2), and murine interleukin-12 (mIL-12).
Main Methods:
- Establishment of liver tumors using intrahepatic implantation of the MCA-26 colon carcinoma cell line in BALB/c mice.
- Intratumoral transfer of recombinant adenoviruses encoding HSV-tk and mIL-2 genes.
- Construction and testing of a recombinant adenovirus expressing the mIL-12 gene.
Main Results:
- Intratumoral transfer of HSV-tk and mIL-2 genes resulted in significant hepatic tumor regression.
- This gene therapy approach induced systemic antitumoral immunity and prolonged median survival from 22 to 35 days.
- Recombinant adenovirus expressing mIL-12 alone significantly increased survival, with 25% of animals surviving over 70 days, suggesting potent anti-tumor effects.
Conclusions:
- Recombinant adenoviral gene therapy, particularly with cytokine genes like IL-12, is a promising strategy for treating hepatic metastases of colon carcinoma.
- Local expression of IL-12 demonstrates significant therapeutic potential and warrants further investigation for metastatic colon cancer.
- While initial immune responses were observed, gradual decline led to tumor recurrence, highlighting the need for sustained therapeutic effects.